Hans Henrik Chrois Christensen
Finanzdirektor/CFO bei Imcheck Therapeutics SAS
Aktive Positionen von Hans Henrik Chrois Christensen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Geschäftsführer | 17.03.2020 | - |
Finanzdirektor/CFO | 17.03.2020 | - |
Karriereverlauf von Hans Henrik Chrois Christensen
Ehemalige bekannte Positionen von Hans Henrik Chrois Christensen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EXIQON A/S | Finanzdirektor/CFO | 01.01.2007 | 05.07.2016 |
Investor Relations Kontakt | 01.01.2007 | 05.07.2016 | |
Public Communications Contact | 01.01.2007 | 05.07.2016 | |
International N&H Denmark ApS
International N&H Denmark ApS Food: Major DiversifiedConsumer Non-Durables DuPont Nutrition Biosciences ApS is engaged in the production of food enzymes, products and pharmaceutical grade excipients for food products. It operates through the following divisions: Enablers, BioActives, Sweeteners, Cultures, Genecor and Sales and Application Food Ingredients. The Enablers division develops, produces and markets emulsifiers, hydrocolloids, and tailored systems that enable food & beverage manufactureres to make appealing products. The BioActives division is comprised of the Cultures and Sweeteners divisions. It offers food cultures and protective solutions, speciality sweeteners, health ingredients, and microorganisms for agriculture and animal nutrition. The Genencor division develops innovative enzymes and bioproducts to reduce the environmental impact of the cleaning, textile, fuel, and chemical industries. The sales and Application food Ingredients division manages and budgets global key accounts. The company was founded in 1989 and is headquartered Copenhagen, Denmark | General Counsel | 01.01.2002 | 01.01.2002 |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Finanzdirektor/CFO | 01.01.2007 | - |
Ausbildung von Hans Henrik Chrois Christensen
University of Copenhagen | Graduate Degree |
Statistik
International
Dänemark | 5 |
Frankreich | 2 |
Operativ
Director of Finance/CFO | 3 |
General Counsel | 1 |
Graduate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Non-Durables | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
International N&H Denmark ApS
International N&H Denmark ApS Food: Major DiversifiedConsumer Non-Durables DuPont Nutrition Biosciences ApS is engaged in the production of food enzymes, products and pharmaceutical grade excipients for food products. It operates through the following divisions: Enablers, BioActives, Sweeteners, Cultures, Genecor and Sales and Application Food Ingredients. The Enablers division develops, produces and markets emulsifiers, hydrocolloids, and tailored systems that enable food & beverage manufactureres to make appealing products. The BioActives division is comprised of the Cultures and Sweeteners divisions. It offers food cultures and protective solutions, speciality sweeteners, health ingredients, and microorganisms for agriculture and animal nutrition. The Genencor division develops innovative enzymes and bioproducts to reduce the environmental impact of the cleaning, textile, fuel, and chemical industries. The sales and Application food Ingredients division manages and budgets global key accounts. The company was founded in 1989 and is headquartered Copenhagen, Denmark | Consumer Non-Durables |
Exiqon A/S
Exiqon A/S Miscellaneous Commercial ServicesCommercial Services Exiqon A/S engages in the development of solutions for ribonucleic acid research and analysis through its Locked Nucleic Acid proprietary technology. Its products and services are used by researchers in academia, biotech, and pharmaceutical companies around the world to make discoveries about the correlation between gene activity and the development of disease. The company was founded by Mikael Ørum, Henrik Ørum and Troels Koch on November 1, 1995 and is headquartered in Copenhagen, Denmark. | Commercial Services |
Pharmexa A/S
Pharmexa A/S Pharmaceuticals: MajorHealth Technology Pharmexa A/S is a leading company in the field of active immunotherapy for the treatment of serious chronic diseases. Pharmexa's proprietary AutoVac(tm) technology platform is broadly applicable, but the company has focused its resources on a number of cancer forms and chronic inflammatory diseases, with research and development programs targeted towards breast cancer, rheumatoid arthritis and bone degeneration | Health Technology |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Health Technology |